Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Shinichi Sato
        • Nancy Worrell
        • Patti Oto
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX727 Oral DNMT inhibitor (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 20072 / SuperGen’s CLIMB™ Technology Identifies Lead Pim Kinase Inhibito...

SuperGen’s CLIMB™ Technology Identifies Lead Pim Kinase Inhibitors

10 December 2007/in 2007, News /by webadmin

SuperGen’s CLIMB™ Technology Identifies Lead Pim Kinase Inhibitors

/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin /wp-content/uploads/2019/11/logo_white.png webadmin2007-12-10 12:09:462016-11-28 13:36:00SuperGen’s CLIMB™ Technology Identifies Lead Pim Kinase Inhibitors

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer... SuperGen’s Novel Hypomethylating Agent Highlighted at American Society...
Scroll to top
By continuing to use this website you will be agreeing to our Terms & Conditions, our Privacy Policy, and the use of cookies.continue